【摘要】 阿尔茨海默病(AD)是一种常见的神经退行性疾病,患病人数众多,给家庭、社会带来沉重的经济负担。由于AD的发病机制尚未阐明,抗AD新药开发面临巨大挑战,迄今尚未找到治愈AD的有效治疗手段和药物。全球各大制药公司和研究机构均高度关注抗AD药物的研发进展,尤其是处于临床研究阶段的抗AD药物。根据药物作用靶点和机制,包括减少β-淀粉样蛋白、平衡Tau蛋白、调节神经递质、平衡Ca2+水平、抗氧化应激、抑制炎性反应、调节糖代谢和激素水平等,对目前抗AD小分子药物临床研究的新进展进行综述。更多还原

【Abstract】 Alzheimer’s disease(AD) is a common progressive multifarious neurodegenerative disease with a high prevalence, which brings huge burden to families and society. Since the mechanism of AD is still unclear, research and development of anti-AD drugs are facing big challenges with very little progress in searching for effective therapies and drugs. Pharmaceutical companies and research institutions worldwide are highly concerned with AD drug development, especially drugs in clinical phase. Herein, this paper reviewed the current progress in the clinical development of small-molecule anti-AD drugs with different targets and mechanisms, including reducing amyloid-β protein, balancing neurofibrillary tangle, regulating neurotransmission disorder, balancing calcium ion, countering oxidative stress, suppressing neuroinflammation,and regulating glucose metabolism disorder.更多还原